• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

News &
Media

  • Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour

    17 June 2022
    Stockhead

    The company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.

    View More
  • Neurotech International reports positive preclinical data from combination study

    14 June 2022
    BiotechDispatch

    Neurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.

    View More
  • ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac

    9 June 2022
    Stockhead

    Neurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.

    View More
  • Neurotech International (ASX:NTI) sees preclinical success with combination therapies

    9 June 2022
    The Market Herald

    Neurotech International (NTI) has reported preclinical research demonstrating its proprietary cannabis strain can improve Diclofenac efficacy at low doses.

    View More
  • Neurotech International (ASX: NTI) – Webinar Presentation

    6 June 2022
    Sharecafe

    Dr. Alexandra Andrews – CEO – Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of its proprietary cannabis strains.

    View More
  • Webinar Recap – NTI, MHK, RPM & ESK

    6 June 2022
    Sharecafe
    View More
  • Australia’s top 20 cannabis companies

    26 May 2022
    Business News Australia

    A report from FreshLeaf Analytics forecasts Australian medicinal cannabis sales of $423 million for 2022, up from an estimated $230 million in 2021. As prices for practically everything rose last year, medicinal cannabis prices went down on average, opening up more budgets to treatment.

    View More
  • Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEO

    3 March 2022
    The Market Herald

    Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

    She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.

    View More
  • Neurotech International Phase I/II Autism Results Due this Quarter

    6 October 2021
    Bioshares

    In July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.

    View More
Previous
1 2 3 4 5
Next

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1675263534anoit1675263534anret1675263534nihce1675263534torue1675263534n@ofn1675263534i1675263534

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus